GYRE

NASDAQ 已收盘

Gyre Therapeutics

4.52 USD
▲+0.18+4.15%
盘后 4.56 +0.88%
2026-11-19
市值
$460.79M
市盈率
—
EPS
-0.26
股息率
—
52 周区间
3.97 – 9.14
成交量
268.93K
Beta
4.92
目标价
18.67
52W 低 3.9752W 高 9.14
价格走势

公司简介

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated l...